With winter on its way and the flu season about to begin Londoners are being offered the opportunity to sign up for a unique clinical trial to test a new DNA Vaccine. The trial, which has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA), will test for the first time whether a DNA vaccine can protect people from infection with influenza.
If successful, this challenge study could pave the way for DNA vaccines such as this H3 vaccine for annual flu and PowderMed’s H5N1 pandemic vaccine, to reach market approval. PowderMed also started a trial on the H5N1 DNA vaccine last month.
PowderMed’s Chief Medical Officer, Dr John Beadle said “This particular trial is unique because it will be the first to assess the ability of our DNA vaccine to protect human volunteers against flu. What we are looking for are people willing to be vaccinated and then later challenged with an annual flu virus. Some of them may get a mild form of influenza like illness, but our previous data suggests that those who are vaccinated may be protected. All volunteers will receive, at the end of the study, treatment with Tamiflu a licensed antiviral drug”.
This trial is one of three being conducted this year by UK company PowderMed to assess the ability of DNA vaccines to protect against annual and pandemic influenza. PowderMed’s DNA vaccines use a proprietary needle-free system to deliver microscopic gold particles coated with DNA at supersonic speed into the immune cells of the skin. Previous studies have shown that these vaccines can protect animals from challenges with either annual or bird flu viruses and produce a protective level of immune response in humans.
The first phase of the trial is being conducted at Guys Drug Research Unit (GDRU), Quintiles UK Ltd in London. Dr Tim Mant, Senior Medical Advisor, GDRU said that “Annual flu is debilitating for many and life threatening for some; flu is a major public health issue and we feel it is important to contribute to knowledge about potential new vaccines. We are currently screening volunteers to determine whether they may be eligible to enroll in this influenza vaccine study.”
Later in the trial the volunteers will be accommodated for ten days in a residential facility, where they will be challenged with an enfeebled version of the H3N2 strain of influenza virus which is known to cause annual influenza in non-immunised people. At the end of this period the volunteers will all be given Tamiflu, an antiviral drug, already approved for use in the UK to reduce the duration of any potential influenza symptoms.
Full details of this clinical study and directions for potential volunteers can be found at www.clinicaltrials.gov. Anyone interested, who is otherwise healthy and aged between 18 and 50, should contact Quintiles at Guys Drugs Research Unit on 0800 634 1130.
Christelle Kerouedan | alfa
Cancer diagnosis: no more needles?
25.05.2018 | Christian-Albrechts-Universität zu Kiel
Less is more? Gene switch for healthy aging found
25.05.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences